ADBiotech Co., Ltd.
Financials
Valuation Metrics
ADBiotech Co., Ltd.'s Market Cap is ₩495B. At end of 2025 it was ₩553B. Ranked #1781 of 2,421 in KR market (top 74%), #1088 of 1,640 on KOSDAQ (top 66%), #190 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 82%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 49.50B KRW | KR#1,781/2,421 Sec#190/231 |
| Revenue | 12.57B KRW | KR#2,252/2,421 Sec#169/231 |
| Net Income | -3.55B KRW | KR—/2,421 Sec—/231 |
| Total Assets | 53.93B KRW | KR#2,174/2,421 Sec#195/231 |
| Net Assets | 26.46B KRW | KR#2,214/2,421 Sec#202/231 |
| Employees | 57 | KR#1,989/2,421 Sec#177/231 |
| Value | ||
| P/B | 1.87x | KR#1,899/2,421 Sec#140/231 |
| P/S | 3.94x | KR#2,081/2,421 Sec#135/231 |
| FCF Yield | -3.43% | KR—/2,421 Sec—/231 |
| Profitability | ||
| ROE | -13.42% | KR#1,996/2,421 Sec#152/231 |
| ROA | -6.59% | KR#1,997/2,421 Sec#147/231 |
| Op. Margin | -35.09% | KR#2,197/2,421 Sec#155/231 |
| Revenue Growth | 4.45% | KR#1,233/2,421 Sec#121/231 |
| Financial Health | ||
| Debt Ratio | 103.81% | KR#1,593/2,421 Sec#183/231 |
| Total Debt | 27.08B KRW | KR#1,273/2,421 Sec#99/231 |
| FCF | -1.70B KRW | KR#1,321/2,421 Sec#103/231 |
| Cash | 12.11B KRW | KR#1,575/2,421 Sec#131/231 |
| Current Ratio | 1.09x | KR#1,620/2,421 Sec#162/231 |
| Performance | ||
| 1Y Return | -50.19% | KR#2,060/2,421 Sec#189/231 |
| 1M Return | -29.40% | KR#2,353/2,421 Sec#221/231 |
| From 52W High | -58.54% | KR#1,800/2,421 Sec#136/231 |
| 1Y MDD | -67.63% | KR#1,872/2,421 Sec#159/231 |
| Trading | ||
| Volume | 131,807 shares | KR#650/2,421 Sec#57/231 |
| Trading Value | 240.7M KRW | KR#1,203/2,421 Sec#122/231 |
| Foreign Own. | 1.05% | KR#2,019/2,421 Sec#198/231 |
| Per Share | ||
| EPS | -130 KRW | KR—/2,421 Sec—/231 |
| BPS | 972 KRW | KR#2,312/2,421 Sec#213/231 |
Company Info
Addbio Tech, established in 2000 and headquartered in Chuncheon-si, Gangwon-do, is an eco-friendly biotechnology company researching immune antibodies to develop vaccines and antibiotic alternatives. The company possesses key pipelines, including IgY immune egg yolk antibodies, VHH antibodies, microbial agents, and scFv antibodies, ensuring high stability through both egg-derived and camelid-derived antibody technologies. Addbio Tech is developing products to meet the growing demand for livestock infectious disease solutions and vaccine alternatives, actively expanding its global market presence, particularly through China and Southeast Asia.